Squarepoint’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-181,978
| Closed | -$8.89M | – | 4862 |
|
|
2025
Q2 | $8.89M | Buy |
181,978
+171,297
| +1,604% | +$8.13M | 0.01% | 1135 |
|
|
2025
Q1 | $544K | Sell |
10,681
-23,290
| -69% | -$1.16M | ﹤0.01% | 3214 |
|
|
2024
Q4 | $1.53M | Sell |
33,971
-297,736
| -90% | -$12.7M | ﹤0.01% | 2656 |
|
|
2024
Q3 | $12.3M | Buy |
331,707
+208,817
| +170% | +$6.99M | 0.02% | 847 |
|
|
2024
Q2 | $3.76M | Buy |
+122,890
| New | +$3.98M | 0.01% | 1572 |
|
|
2023
Q4 | – | Sell |
-13,500
| Closed | -$303K | – | 4393 |
|
|
2023
Q3 | $303K | Buy |
+13,500
| New | +$502K | ﹤0.01% | 3160 |
|
|
2023
Q1 | – | Sell |
-64,967
| Closed | -$2.48M | – | 3694 |
|
|
2022
Q4 | $2.48M | Sell |
64,967
-74,456
| -53% | -$3.1M | 0.01% | 1244 |
|
|
2022
Q3 | $7M | Buy |
139,423
+49,584
| +55% | +$2.43M | 0.04% | 581 |
|
|
2022
Q2 | $3.6M | Buy |
89,839
+42,783
| +91% | +$1.5M | 0.02% | 853 |
|
|
2022
Q1 | $1.76M | Buy |
+47,056
| New | +$1.81M | 0.01% | 1235 |
|
|
2021
Q2 | – | Sell |
-6,271
| Closed | -$297K | – | 3603 |
|
|
2021
Q1 | $297K | Buy |
+6,271
| New | +$372K | ﹤0.01% | 2405 |
|
|
2020
Q4 | – | Sell |
-13,638
| Closed | -$638K | – | 3194 |
|
|
2020
Q3 | $638K | Buy |
13,638
+8,109
| +147% | +$399K | 0.01% | 1245 |
|
|
2020
Q2 | $281K | Sell |
5,529
-4,326
| -44% | -$213K | ﹤0.01% | 1637 |
|
|
2020
Q1 | $440K | Buy |
+9,855
| New | +$496K | 0.01% | 1110 |
|
|
2019
Q4 | – | Sell |
-29,613
| Closed | -$1M | – | 2737 |
|
|
2019
Q3 | $1M | Buy |
+29,613
| New | +$1.29M | 0.01% | 1236 |
|
|
2019
Q2 | – | Sell |
-40,685
| Closed | -$1.53M | – | 2613 |
|
|
2019
Q1 | $1.53M | Sell |
40,685
-1,602
| -4% | -$53.8K | 0.02% | 885 |
|
|
2018
Q4 | $1.45M | Buy |
42,287
+13,087
| +45% | +$471K | 0.02% | 789 |
|
|
2018
Q3 | $1.37M | Sell |
29,200
-12,957
| -31% | -$536K | 0.02% | 850 |
|
|
2018
Q2 | $1.42M | Buy |
42,157
+12,480
| +42% | +$389K | 0.02% | 756 |
|
|
2018
Q1 | $803K | Buy |
29,677
+340
| +1% | +$8.62K | 0.01% | 888 |
|
|
2017
Q4 | $489K | Buy |
+29,337
| New | +$497K | 0.01% | 1224 |
|
|
2017
Q3 | – | Sell |
-21,049
| Closed | -$386K | – | 1825 |
|
|
2017
Q2 | $386K | Buy |
+21,049
| New | +$284K | 0.01% | 1045 |
|
|
2017
Q1 | – | Sell |
-41,643
| Closed | -$454K | – | 1842 |
|
|
2016
Q4 | $454K | Buy |
41,643
+15,165
| +57% | +$159K | 0.02% | 891 |
|
|
2016
Q3 | $371K | Buy |
+26,478
| New | +$215K | 0.02% | 661 |
|
|
2016
Q2 | – | Sell |
-50,800
| Closed | -$327K | – | 1302 |
|
|
2016
Q1 | $327K | Buy |
50,800
+43,700
| +615% | +$758K | 0.03% | 795 |
|
|
2015
Q4 | $230K | Sell |
7,100
-6,800
| -49% | -$200K | 0.03% | 917 |
|
|
2015
Q3 | $371K | Buy |
+13,900
| New | +$595K | 0.09% | 229 |
|
|
2015
Q2 | – | Sell |
-10,000
| Closed | -$609K | – | 576 |
|
|
2015
Q1 | $609K | Buy |
+10,000
| New | +$610K | 0.21% | 153 |
|
Other funds holding PTCT
RI
AC
Squarepoint's PTCT Position: Q3 2025 in Review
Squarepoint sold out of PTC Therapeutics (PTCT) in Q3 2025, closing a stake of 181,978 shares — an estimated $8.89M sold.
Squarepoint first reported a position in PTCT in Q1 2015 and held it in 28 quarters. The position peaked at $12.3M in Q3 2024. 294 funds tracked by Wall St. Rank hold PTCT as of Q3 2025.
- Squarepoint reported no remaining PTC Therapeutics position as of Q3 2025 after selling out during the quarter.
- Squarepoint sold 181,978 PTC Therapeutics shares in Q3 2025, an estimated $8.89M.
- Squarepoint first reported a position in PTC Therapeutics in Q1 2015 and held it in 28 quarters.
- Squarepoint's PTC Therapeutics position peaked at $12.3M in Q3 2024.
- 294 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2025.
Based on Squarepoint's 13F filing for Q3 2025, filed 14 Nov 2025.